Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Prepaid Assets: 2009-2025

Historic Prepaid Assets for Cumberland Pharmaceuticals (CPIX) over the last 17 years, with Sep 2025 value amounting to $1.4 million.

  • Cumberland Pharmaceuticals' Prepaid Assets fell 29.41% to $1.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.4 million, marking a year-over-year decrease of 29.41%. This contributed to the annual value of $2.8 million for FY2024, which is 7.89% down from last year.
  • Latest data reveals that Cumberland Pharmaceuticals reported Prepaid Assets of $1.4 million as of Q3 2025, which was down 12.73% from $1.6 million recorded in Q2 2025.
  • In the past 5 years, Cumberland Pharmaceuticals' Prepaid Assets ranged from a high of $3.7 million in Q3 2022 and a low of $1.3 million during Q3 2021.
  • Moreover, its 3-year median value for Prepaid Assets was $2.3 million (2023), whereas its average is $2.3 million.
  • In the last 5 years, Cumberland Pharmaceuticals' Prepaid Assets spiked by 196.95% in 2022 and then plummeted by 47.28% in 2023.
  • Over the past 5 years, Cumberland Pharmaceuticals' Prepaid Assets (Quarterly) stood at $3.3 million in 2021, then dropped by 7.63% to $3.1 million in 2022, then declined by 1.94% to $3.0 million in 2023, then decreased by 7.89% to $2.8 million in 2024, then fell by 29.41% to $1.4 million in 2025.
  • Its Prepaid Assets stands at $1.4 million for Q3 2025, versus $1.6 million for Q2 2025 and $2.2 million for Q1 2025.